Selpercatinib (Synonyms: 塞尔帕替尼; LOXO-292)
目录号: PL10967 纯度: ≥99%
CAS No. :2152628-33-4
商品编号 规格 价格 会员价 是否有货 数量
PL10967-5mg 5mg ¥741.82 请登录
PL10967-10mg 10mg ¥1236.36 请登录
PL10967-25mg 25mg ¥2720.00 请登录
PL10967-50mg 50mg ¥4327.27 请登录
PL10967-100mg 100mg ¥8036.36 请登录
PL10967-200mg 200mg 询价 询价
PL10967-500mg 500mg 询价 询价
PL10967-10mM*1mLinDMSO 10mM*1mLinDMSO ¥853.09 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
Selpercatinib
中文别名
Selpercatinib;司陪替尼;塞尔帕替尼
英文名称
Selpercatinib
英文别名
Selpercatinib;CEGM9YBNGD;6-(2-Hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo(3.1.1)heptan-3-yl)pyridin-3-yl)pyrazolo(1,5-a)pyridine-3-carbonitrile;6-(2-hydroxy-2-methylpropoxy)-4-(6-(6-((6-methoxypyridin-3-yl)methyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)pyridin-3-yl)pyrazolo[1,5-a]pyridine-3-carbonitrile;6-(2-hydroxy-2-methylpropoxy)-4-[6-[6-[(6-methoxypyridin-3-yl)methyl]-3,6-diazabicyclo[3.1.1]heptan-3-yl]pyridin-3-yl]pyrazolo[1,5-a
Cas No.
2152628-33-4
分子式
C29H31N7O3
分子量
525.60
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
Selpercatinib (LOXO-292) 是一种有效的选择性 RET 激酶抑制剂,抑制 RET (WT),RET (V804M) 和 RET (G810R),其 IC50 值分别为 14.0 nM,24.1 nM 和 530.7 nM。Selpercatinib 具有抗肿瘤作用。
生物活性
Selpercatinib (LOXO-292) is a potent, selective RET kinase inhibitor with IC 50 values of 14.0 nM, 24.1 nM, and 530.7 nM for RET (WT), RET (V804M), and RET (G810R), respectively. Selpercatinib has anticancer activity.
性状
Solid
IC50 & Target[1][2]
IC50: 14.0 nM (RET), 24.1 nM (RET), and 530.7 nM (RET)
体内研究(In Vivo)
Selpercatinib (LOXO-292; 10 mg/kg; i.g.; for 0-2 h) has good pharmacokinetics after oral gavage in FVB/NRj mice.
Pharmacokinetic Parameters of Selpercatinib in FVB/NRj mice.
Administration i.g. (10 mg/kg) T max (h) 1.8
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
ClinicalTrial
参考文献
[1]. ?entürk R, et, al. Quantitative bioanalytical assay for the selective RET inhibitors selpercatinib and pralsetinib in mouse plasma and tissue homogenates using liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122131.
[2]. Steven W. Andrews, et al. Substituted pyrazolo[1,5-a]pyridine compounds as ret kinase inhibitors. WO2018071447A1.
溶解度数据
In Vitro: DMSO : 62.5 mg/mL (118.91 mM; Need ultrasonic)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2